RAPP
Rapport Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +23.2% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +3 | 25.14M | $1.04B | +5 | −2 |
| Q1 2026 | 69 | +1 | 25.07M | $783.61M | +5 | −4 |
| Q4 2025 | 68 | +1 | 25.43M | $771.51M | +1 | — |
| Q3 2025 | 16 | +4 | 15.68M | $465.84M | +4 | — |
| Q2 2025 | 9 | +1 | 10.01M | $113.83M | +2 | −1 |
| Q1 2025 | 5 | 0 | 1.86M | $18.69M | +1 | −1 |
| Q4 2024 | 5 | 0 | 2.06M | $36.50M | — | — |
| Q3 2024 | 4 | -2 | 1.81M | $36.50M | +1 | −3 |
| Q2 2024 | 6 | — | 2.18M | $50.21M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 6.92M | +26.4% | $205.43M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Goldman Sachs Group ✦ | 2.42M | — | $71.93M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | The Vanguard Group ✦ (passive) | 1.63M | +46.9% | $48.31M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 4 | BlackRock ✦ (passive) | 1.57M | +28.6% | $46.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×7 |
| 5 | T. Rowe Price ✦ | 1.10M | -27.7% | $32.74M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | Geode Capital Management ✦ (passive) | 533.40K | +60.1% | $15.85M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Adage Capital Partners ✦ | 450.00K | New | $13.37M | 0.0% | New | 1 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passive) | 371.63K | +24.4% | $11.04M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Morgan Stanley ✦ | 274.57K | — | $8.15M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 10 | Millennium Management ✦ | 154.17K | New | $4.58M | 0.0% | New | 1 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 104.88K | New | $3.11M | 0.0% | New | 1 | SEC ↗ ×2 |
| 12 | Wellington Management ✦ | 62.82K | New | $1.87M | 0.0% | New | 1 | SEC ↗ ×3 |
| 13 | Renaissance Technologies ✦ | 35.30K | +126.3% | $1.05M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 21.50K | +8.9% | $638,550 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 20.62K | +21.5% | $612,474 | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 16 | JPMorgan Chase ✦ | 19.97K | — | $593,048 | 0.0% | n/c | 1 | SEC ↗ ×6 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $13.37M | 0.0% |
| Millennium Management | $4.58M | 0.0% |
| Citadel Advisors | $3.11M | 0.0% |
| Wellington Management | $1.87M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 52.47M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.15K sh · $35,167
Officer, Director · 3.38K sh · $108,106
Officer · 7.92K sh · $261,813
Officer · 2.08K sh · $70,043
Officer, Director · 1.95K sh · $76,230
Officer, Director · 43 sh · $1,765
Officer, Director · 215 sh · $8,570
Officer, Director · 1.07K sh · $49,190
Officer, Director · 7.14K sh · $325,308
Officer · 16.20K sh · $827,184
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology